Advertisement

Agents and Actions

, Volume 5, Issue 2, pp 137–144 | Cite as

Substances that increase the cyclic AMP content prevent platelet aggregation and the concurrent release of pharmacologically active substances evoked by arachidonic acid

  • B. B. Vargaftig
  • M. Chignard
Immunosuppression and Inflammation
Received:
Revised:

Abstract

Arachidonic acid-induced platelet aggregation was inhibited by prostaglandins E1 and F2α (PGE1 and PGF2α), papaverine and dibutyryl cyclic AMP. Prostaglandin E2 displayed a biphasic effect, as concentrations below 2 μM potentiated aggregation, whereas concentrations above it were inhibitory. Isoproterenol (up to 10 mM) failed to block aggregation but inhibition was uncovered in presence of adrenergic α-blocking agents. Isoproterenol potentiated aggregation due to sub-threshold amounts of arachidonic acid, and this effect, but not that due to PGE2, was suppressed by the α-blocking agents. Isoproterenol and PGE2 appear thus to enhance arachidonic acid-induced platelet aggregation after interacting with different receptor sites. The yield of rabbit aorta contracting activity formed during AA-induced aggregation was markedly reduced by PGE1, dibutyryl cyclic AMP and high concentrations of PGE2, and was increased by low concentrations of the latter. PG-like activity was not significantly reduced when aggregation and generation of rabbit aorta contracting activity were inhibited by bibutyryl cyclic AMP. It is hypothesized that interaction of human platelets and arachidonic acid results in formation of different pharmacologically active materials, possibly bearing similar lipoperoxide structures. Generation of one portion of these materials is controlled by the adenyl cyclase-cyclic AMP system, whereas another portion, that comprises the natural PG, is cyclic AMP-independent. Prostaglandins formed during platelet aggregation have a regulatory role and modulate the platelet response, rather than constitute a trigger stimulus for aggregation.

Keywords

Arachidonic Acid PGE2 Isoproterenol Papaverine Adenyl 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    H.R. Bourne, L.M. Lichtenstein, K.L. Melmon, C.S. Henney, Y. Weinstein andG.M. Shearer,Modulation of Inflammation and Immunity by Cyclic AMP, Science184, 19–28 (1974).PubMedGoogle Scholar
  2. [2]
    J. Kloeze,Influence of Prostaglandins on Platelet Adhesiveness and Platelet Aggregation, in:Prostaglandins, Nobel Symposium 2 (Eds. S. Bergström and B. Samuelsson; Almquist and Wiksell, Stockholm 1967), p. 241–252.Google Scholar
  3. [3]
    B.B. Vargaftig andP. Zirinis,Platelet Aggregation Induced by Arachidonic Acid is Accompanied by Release of Potential Inflammatory Mediators Distinct from PGE 2 and PGF 2a, Nature New Biol.244, 114–116 (1973).PubMedGoogle Scholar
  4. [4]
    J. Clausen andK.C. Srivastava,The Synthesis of Prostaglandins in Human Platelets, Lipids7, 246–250 (1972).PubMedGoogle Scholar
  5. [5]
    B.B. Vargaftig andN. Dao Hai,Paradoxical Inhibition of the Effects of Bradykinin by some Sulfhydryl Reagents, Experientia28, 59–62 (1972).CrossRefPubMedGoogle Scholar
  6. [6]
    R. Gryglewski andJ.R. Vane,The Release of Prostaglandins and Rabbit Aorta Contracting Substance (RCS) from Rabbit Spleen and its Antagonism by Anti-Inflammatory Drugs, Br. J. Pharmac.45, 37–47 (1972).Google Scholar
  7. [7]
    B.B. Vargaftig andN. Dao,Release of Vasoactive Substances from Guinea-Pig Lungs by Slow-Reacting Substance C and Arachidonic Acid, Pharmacology6, 99–108 (1971).PubMedGoogle Scholar
  8. [8]
    J.B. Smith andA.L. Willis,Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets, Nature New Biol.231, 235–237 (1971).PubMedGoogle Scholar
  9. [9]
    J.R. Vane,Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs, Nature New Biol.231, 232–235 (1971).PubMedGoogle Scholar
  10. [10]
    A.L. Willis,Platelet Synthesis of Pro-Aggregating Material from Arachidonate and its Blockade by Aspirin, CirculationXLVIII, Suppl. IV–55 (1973).Google Scholar
  11. [11]
    B.B. Vargaftig, Y. Tranier andM. Chignard,Inhibition by Sulfhydryl Agents of Arachidonic Acid-Induced Platelet Aggregation and Release of Potential Inflammatory Substances, Prostaglandins8, 133–156 (1974).CrossRefPubMedGoogle Scholar
  12. [12]
    B.B. Vargaftig, Y. Tranier andM. Chignard,Blockade by Metal Complexing Agents and by Catalase of the Effects of Arachidonic Acid on Platelets: Relevance to the Study of Anti-Inflammatory Mechanisms, Eur. J. Pharmac., accepted for publication (1975).Google Scholar
  13. [13]
    G.V.R. Born,Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal, Nature194, 927–929 (1962).PubMedGoogle Scholar
  14. [14]
    J.R. Vane,The use of Isolated Organs for Detecting Active Substances in the Circulating Blood, Br. J. Pharmac.23, 360–373 (1964).Google Scholar
  15. [15]
    H. Shio andP.W. Ramwell, Effect of Prostaglandin E2 and Aspirin on the Secondary Aggregation of Human Platelets, Nature New Biol.236, 45–46 (1972).CrossRefPubMedGoogle Scholar
  16. [16]
    E.W. Salzman, P.C. Kensler andL. Levine,Cyclic 3′,5′-Adenosine Monophosphate in human Blood Platelets, Ann. N.Y. Acad. Sci.201, 61–71 (1972).PubMedGoogle Scholar
  17. [17]
    L. Triner, Y. Vulliemoz, I. Schwartz andG.G. Nahas,Cyclic Phosphodiesterase Activity and the Action of Papaverine, Biochem. Biophys. Res. Comm.40, 64–69 (1970).CrossRefPubMedGoogle Scholar
  18. [18]
    T. Posternak, E.W. Sutherland andW.F. Henion,Derivatives of Cyclic 3′,5′-adenosine Monophosphate, Biochim. Biophys. Acta65, 558–560 (1962).CrossRefPubMedGoogle Scholar
  19. [19]
    R.J. Haslam andM.D. Mc Glenaghan,Effects of Collagen and of Aspirin on the Concentration of Guanosine 3′,5′-cyclic Monophosphate in Human Blood Platelets: Measurement by a Prelabelling Technique, Biochem. J.138, 317–320 (1974).PubMedGoogle Scholar
  20. [20]
    M. Kaliner andK.F. Austen,Cyclic Nucleotides and Modulation of Effector Systems of Inflammation, Biochem. Pharmac.23, 763–771 (1974).CrossRefGoogle Scholar
  21. [21]
    E. Gillespie, M.D. Valentine andL.M. Lichtenstein,Cyclic AMP Metabolism in Asthma: Studies with Leukocytes and Lymphocytes, J. Allergy clin. Immun.53, 27–33 (1974).CrossRefPubMedGoogle Scholar
  22. [22]
    L.J. Ignarro, T.F. Lint andW.J. George,Hormonal Control of Lysosomal Enzyme Release from Human Neutrophils, J. exp. Med.139, 1395–1414 (1974).CrossRefPubMedGoogle Scholar
  23. [23]
    L.M. Lichtenstein andS. Margolis,Histamine Release in vitro: Inhibition by Catecholamines and Methylxantines, Science161, 902–903 (1968).PubMedGoogle Scholar
  24. [24]
    M. Hamberg, J. Svensson, T. Wakabayashi andB. Samuelsson,Isolation and Structure of two Prostaglandin Endoperoxides that Structure of two Aggregation, Proc. Nat. Acad. Sci.2, 345–349 (1974).Google Scholar
  25. [25]
    A.L. Willis, F.M. Vane, D.C. Kuhn, C.G. Scott andM. Petrin,An Endoperoxide Aggregator (Lass), Formed in Platelets in Response to Thrombotic Stimuli, Prostaglandins8, 453–507 (1974).CrossRefPubMedGoogle Scholar
  26. [26]
    M. Hamberg, P. Hedqvist, K. Strandberg, J. Svensson andB. Samuelsson,Prostaglandin Endoperoxides IV. Effects on Smooth Muscle, Life Sci.16, 451–462 (1975).CrossRefPubMedGoogle Scholar
  27. [27]
    R. Gryglewski andJ.R. Vane,The Generation from Arachidonic Acid of a Rabbit Aorta Contracting Substance (RCS) by a Microsomal Enzyme Preparation which also Generates Prostaglandins, Br. J. Pharmac.46, 449–457 (1972).Google Scholar
  28. [28]
    T. Dakhil andW. Vogt,Hydroperoxyde als Träger der darmerregenden Wirkung hochungesättigter Fettsäuren, Arch. exp. Path. Pharmak.243, 174–186 (1962).Google Scholar
  29. [29]
    S.H. Fereira andB.B. Vargaftig,Generation of Rabbit Aorta Contracting Substance in Blood by Slow Reacting Substance C and its Blockade by Non-Steroid Anti-Inflammatory Drugs, Biorheology10, 288–289 (1973).Google Scholar
  30. [30]
    S.H. Ferreira andB.B. Vargaftig,Inhibition by Non-Steroid Anti-Inflammatory Agents of Rabbit Aorta Contracting Activity Generated in Blood by Slow Reacting Substance C, Br. J. Pharmac.50, 543–551 (1974).Google Scholar
  31. [31]
    M. Hamberg, J. Svensson andB. Samuelsson,Prostaglandin Endoperoxides. A New Concept Concerning the Mode of Action and Release of Prostaglandins, Proc. Nat. Acad. Sci.71, 3824–3828 (1974).PubMedGoogle Scholar
  32. [32]
    M.J.G. Harrison, P.R. Emmons andJ.R.A. Mitchell,The Effect of Sulfhydryl and Enzyme Inhibitors on Platelet Aggregation in vitro, Thromb. diath. haemorrh.16, 122–133 (1966).PubMedGoogle Scholar
  33. [33]
    N. Baker andL. Wilson,Inhibition of Tumor Glycolysis by Hydrogen Peroxide Formed from Autoxidation of Unsaturated Fatty Acids, Biochem. Biophys. Res. Comm.11, 60–64 (1963).CrossRefPubMedGoogle Scholar
  34. [34]
    S. A. Saeed andB. T. Warren,On the Mode of Action and Biochemical Properties of Anti-Inflammatory Drugs-I, Biochem. Pharmac.22, 1965–1969 (1973).CrossRefGoogle Scholar
  35. [35]
    D.C.B. Mills andG.C.K. Roberts,Effects of Adrenaline on Human Blood Platelets, J. Physiol. Lond.193, 443–453 (1967).PubMedGoogle Scholar
  36. [36]
    Y.H. Abdulla, β-Adrenergic Receptors in Human Platelets, J. Atheroscler.9, 171–177 (1969).Google Scholar
  37. [37]
    B.B. Weksler, M. Gillick andJ. Pink,Propranolol as an Inhibitor of Platelet Aggregation: Membrane Action, Blood44, 918 (1974).Google Scholar

Copyright information

© Birkhäuser Verlag 1975

Authors and Affiliations

  • B. B. Vargaftig
    • 1
  • M. Chignard
    • 1
  1. 1.Centre de Recherche Merrell InternationalStrasbourgFrance

Personalised recommendations

Cite article

Buy options